The CC chemokine receptor type-2 (CCR2) belongs to the G-protein-coupled receptor superfamily, expressed on the cell surface of immune cells and tumors. CCR2 binds to the CC motif chemokine 2/monocyte chemoattractant protein-1, a CC chemokine, which is produced by various cells, including immune-related cells and tumors. Therefore, the development of sensitive monoclonal antibodies (mAbs) for CCR2 has been desired for treatment and diagnosis. This study established a novel, specific, and sensitive anti-mouse CCR2 (mCCR2) mAb; C2Mab-6 (rat IgG1, kappa), using the mCCR2 synthetic peptide immunization method. C2Mab-6 reacted with mCCR2-overexpressed Chinese hamster ovary-K1 cells and L1210 (murine leukemia) cells, which express endogenous mCCR2 in flow cytometry. Furthermore, C2Mab-6 showed a high binding affinity for both cells. Hence, C2Mab-6 can be a useful tool for analyzing mCCR2-related biological responses, using flow cytometry.
Get full access to this article
View all access options for this article.
References
1.
LutherSA, and CysterJG: Chemokines as regulators of T cell differentiation. Nat Immunol, 2001; 2:102–107.
2.
SokolCL, and LusterAD: The chemokine system in innate immunity. Cold Spring Harb Perspect Biol, 2015; 7:a016303.
3.
NagarshethN, WichaMS, and ZouW: Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol, 2017; 17:559–572.
4.
BalkwillF: Cancer and the chemokine network. Nat Rev Cancer, 2004; 4:540–550.
5.
HughesCE, and NibbsRJB: A guide to chemokines and their receptors. FEBS J, 2018; 285:2944–2971.
6.
SchönebergT, and LiebscherI: Mutations in G protein-coupled receptors: Mechanisms, pathophysiology and potential therapeutic approaches. Pharmacol Rev, 2021; 73:89–119.
7.
BianconiV, SahebkarA, AtkinSL, and PirroM: The regulation and importance of monocyte chemoattractant protein-1. Curr Opin Hematol, 2018; 25:44–51.
8.
DoHTT, LeeCH, and ChoJ: Chemokines and their receptors: Multifaceted roles in cancer progression and potential value as cancer prognostic markers. Cancers (Basel), 2020; 12:287.
9.
LimSY, YuzhalinAE, Gordon-WeeksAN, and MuschelRJ: Targeting the CCL2-CCR2 signaling axis in cancer metastasis. Oncotarget, 2016; 7:28697–28710.
10.
XuM, WangY, XiaR, WeiY, and WeiX: Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting. Cell Prolif, 2021; 54:e13115.
11.
KadomotoS, IzumiK, and MizokamiA: Roles of CCL2-CCR2 axis in the tumor microenvironment. Int J Mol Sci, 2021; 22:8530.
12.
HaoQ, VadgamaJV, and WangP: CCL2/CCR2 signaling in cancer pathogenesis. Cell Commun Signal, 2020; 18:82.
13.
UrbantatRM, VajkoczyP, and BrandenburgS: Advances in chemokine signaling pathways as therapeutic targets in glioblastoma. Cancers (Basel), 2021; 13:2983.
14.
MoadabF, KhorramdelazadH, and AbbasifardM: Role of CCL2/CCR2 axis in the immunopathogenesis of rheumatoid arthritis: Latest evidence and therapeutic approaches. Life Sci, 2021; 269:119034.
15.
CuypersF, SchäferA, SkorkaSB, SurabhiS, TölkenLA, PaulikatAD, KohlerTP, OttoSA, MettenleiterTC, HammerschmidtS, BlohmU, and SiemensN: Innate immune responses at the asymptomatic stage of influenza A viral infections of Streptococcus pneumoniae colonized and non-colonized mice. Sci Rep, 2021; 11:20609.
16.
Midavaine É, CôtéJ, and SarretP: The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers. Cancer Metastasis Rev, 2021; 40:427–445.
17.
LobergRD, DayLL, HarwoodJ, YingC, St JohnLN, GilesR, NeeleyCK, and PientaKJ: CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia, 2006; 8:578–586.
18.
YamadaS, KanekoMK, SayamaY, AsanoT, SanoM, YanakaM, NakamuraT, OkamotoS, HandaS, KomatsuY, NakamuraY, FurusawaY, TakeiJ, and KatoY: Development of novel mouse monoclonal antibodies against human CD19. Monoclon Antib Immunodiagn Immunother, 2020; 39:45–50.
19.
FurusawaY, KanekoMK, and KatoY: Establishment of C20Mab-11, a novel anti-CD20 monoclonal antibody, for the detection of B cells. Oncol Lett, 2020; 20:1961–1967.
20.
FurusawaY, KanekoMK, and KatoY: Establishment of an anti-CD20 monoclonal antibody (C20Mab-60) for immunohistochemical analyses. Monoclon Antib Immunodiagn Immunother, 2020; 39:112–116.
21.
YamadaS, ItaiS, NakamuraT, YanakaM, KanekoMK, and KatoY: Detection of high CD44 expression in oral cancers using the novel monoclonal antibody, C44Mab-5. Biochem Biophys Rep, 2018; 14:64–68.
22.
ItaiS, FujiiY, NakamuraT, ChangYW, YanakaM, SaidohN, HandaS, SuzukiH, HaradaH, YamadaS, KanekoMK, and KatoY: Establishment of CMab-43, a sensitive and specific anti-CD133 monoclonal antibody, for immunohistochemistry. Monoclon Antib Immunodiagn Immunother, 2017; 36:231–235.
23.
HosonoH, OhishiT, TakeiJ, AsanoT, SayamaY, KawadaM, KanekoMK, and KatoY: The anti-epithelial cell adhesion molecule (EpCAM) monoclonal antibody EpMab-16 exerts antitumor activity in a mouse model of colorectal adenocarcinoma. Oncol Lett, 2020; 20:383.
AsanoT, OhishiT, TakeiJ, NakamuraT, NanamiyaR, HosonoH, TanakaT, SanoM, HaradaH, KawadaM, KanekoMK, and KatoY: AntiHER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma. Oncol Rep, 2021; 46:173.
26.
AsanoT, NanamiyaR, TanakaT, KanekoMK, and KatoY: Development of antihuman killer cell lectin-like receptor subfamily G member 1 monoclonal antibodies for flow cytometry. Monoclon Antib Immunodiagn Immunother, 2021; 40:76–80.
27.
TakeiJ, AsanoT, NanamiyaR, NakamuraT, YanakaM, HosonoH, TanakaT, SanoM, KanekoMK, HaradaH, and KatoY: Development of anti-human T cell immunoreceptor with Ig and ITIM domains (TIGIT) monoclonal antibodies for flow cytometry. Monoclon Antib Immunodiagn Immunother, 2021; 40:71–75.
28.
SayamaY, KanekoMK, and KatoY: Development and characterization of TrMab6, a novel antiTROP2 monoclonal antibody for antigen detection in breast cancer. Mol Med Rep, 2021; 23:92.
29.
SayamaY, KanekoMK, TakeiJ, HosonoH, SanoM, AsanoT, and KatoY: Establishment of a novel anti-TROP2 monoclonal antibody TrMab-29 for immunohistochemical analysis. Biochem Biophys Rep, 2021; 25:100902.
30.
YamadaS, ItaiS, NakamuraT, YanakaM, ChangYW, SuzukiH, KanekoMK, and KatoY: Monoclonal antibody L1Mab-13 detected human PD-L1 in lung cancers. Monoclon Antib Immunodiagn Immunother, 2018; 37:110–115.
31.
HosonoH, AsanoT, TakeiJ, SanoM, TanakaT, KanekoMK, and KatoY: Development of an anti-elephant podoplanin monoclonal antibody PMab-265 for flow cytometry. Monoclon Antib Immunodiagn Immunother, 2021; 40:141–145.
32.
TanakaT, AsanoT, SanoM, TakeiJ, HosonoH, NanamiyaR, NakamuraT, YanakaM, HaradaH, FukuiM, SuzukiH, UchidaK, NakagawaT, KatoY, and KanekoMK: Development of monoclonal antibody PMab-269 against California Sea Lion podoplanin. Monoclon Antib Immunodiagn Immunother, 2021; 40:124–133.
33.
KatoY, FurusawaY, SanoM, TakeiJ, NakamuraT, YanakaM, OkamotoS, HandaS, KomatsuY, AsanoT, SayamaY, and KanekoMK: Development of an anti-sheep podoplanin monoclonal antibody PMab-256 for immunohistochemical analysis of lymphatic endothelial cells. Monoclon Antib Immunodiagn Immunother, 2020; 39:82–90.
34.
KatoY, FurusawaY, ItaiS, TakeiJ, NakamuraT, SanoM, HaradaH, YamadaS, and KanekoMK: Establishment of an anticetacean podoplanin monoclonal antibody PMab-237 for immunohistochemical analysis. Monoclon Antib Immunodiagn Immunother, 2019; 38:108–113.
35.
FurusawaY, TakeiJ, SayamaY, YamadaS, KanekoMK, and KatoY: Development of an anti-bear podoplanin monoclonal antibody PMab-247 for immunohistochemical analysis. Biochem Biophys Rep, 2019; 18:100644.
36.
FurusawaY, YamadaS, ItaiS, NakamuraT, TakeiJ, SanoM, HaradaH, FukuiM, KanekoMK, and KatoY: Establishment of a monoclonal antibody PMab-233 for immunohistochemical analysis against Tasmanian devil podoplanin. Biochem Biophys Rep, 2019; 18:100631.
37.
KatoY, FurusawaY, YamadaS, ItaiS, TakeiJ, SanoM, and KanekoMK: Establishment of a monoclonal antibody PMab-225 against alpaca podoplanin for immunohistochemical analyses. Biochem Biophys Rep, 2019; 18:100633.
38.
FurusawaY, YamadaS, NakamuraT, SanoM, SayamaY, ItaiS, TakeiJ, HaradaH, FukuiM, KanekoMK, and KatoY: PMab-235: A monoclonal antibody for immunohistochemical analysis against goat podoplanin. Heliyon, 2019; 5:e02063.
39.
KatoY, YamadaS, FurusawaY, ItaiS, NakamuraT, YanakaM, SanoM, HaradaH, FukuiM, and KanekoMK: PMab-213: A monoclonal antibody for immunohistochemical analysis against pig podoplanin. Monoclon Antib Immunodiagn Immunother, 2019; 38:18–24.
40.
FurusawaY, YamadaS, ItaiS, NakamuraT, YanakaM, SanoM, HaradaH, FukuiM, KanekoMK, and KatoY: PMab-219: A monoclonal antibody for the immunohistochemical analysis of horse podoplanin. Biochem Biophys Rep, 2019; 18:100616.
41.
FurusawaY, KanekoMK, NakamuraT, ItaiS, FukuiM, HaradaH, YamadaS, and KatoY: Establishment of a monoclonal antibody PMab-231 for tiger podoplanin. Monoclon Antib Immunodiagn Immunother, 2019; 38:89–95.
42.
AsanoT, NanamiyaR, TakeiJ, NakamuraT, YanakaM, HosonoH, TanakaT, SanoM, KanekoMK, and KatoY: Development of anti-mouse CC chemokine receptor 3 monoclonal antibodies for flow cytometry. Monoclon Antib Immunodiagn Immunother, 2021; 40:107–112.
43.
TanakaT, NanamiyaR, TakeiJ, NakamuraT, YanakaM, HosonoH, SanoM, AsanoT, KanekoMK, and KatoY: Development of anti-mouse CC chemokine receptor 8 monoclonal antibodies for flow cytometry. Monoclon Antib Immunodiagn Immunother, 2021; 40:65–70.
44.
NanamiyaR, TakeiJ, AsanoT, TanakaT, SanoM, NakamuraT, YanakaM, HosonoH, KanekoMK, and KatoY: Development of anti-human CC chemokine receptor 9 monoclonal antibodies for flow cytometry. Monoclon Antib Immunodiagn Immunother, 2021; 40:101–106.
